Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29062573 | 0.84 | ERN1 (0.52) | TDP1ERN1PTPN1HSD17B10CA1 | |
| SCHEMBL28299606 | 0.80 | TDP1 (0.55) | TDP1ERN1PTPN1HSD17B10SRC | |
| SCHEMBL1758631 | 0.79 | MEN1 (0.50) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL20198141 | 0.79 | TDP1 (0.46) | TDP1ERN1PTPN1HSD17B10SRC | |
| SCHEMBL20198170 | 0.77 | TDP1 (0.43) | TDP1ERN1PTPN1SRCMEN1 | |
| SCHEMBL14532525 | 0.76 | KDM5A (0.58) | ERN1HSD17B10MEN1KMT2APOLB | |
| SCHEMBL1758540 | 0.76 | RAPGEF4 (0.50) | KMT2APOLBALDH1A1KDM4EMAPT | |
| SCHEMBL9753459 | 0.76 | TDP1 (0.50) | TDP1ERN1MEN1KMT2APOLB | |
| SCHEMBL30132193 | 0.75 | CA1 (0.50) | TDP1CA1CA14MEN1KMT2A | |
| SCHEMBL325006 | 0.75 | CA1 (0.50) | TDP1CA1CA14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116621835-B | Synthesis method for synthesizing polycyclic quinoline derivative based on isonitrile | 上海大学 | 2024-05-24 | — | — | CN | claimed |
| CN-116621835-A | Synthesis method for synthesizing polycyclic quinoline derivative based on isonitrile | 上海大学 | 2023-08-22 | — | — | CN | claimed |
| CN-116621835-B | Synthesis method for synthesizing polycyclic quinoline derivative based on isonitrile | 上海大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-116621835-A | Synthesis method for synthesizing polycyclic quinoline derivative based on isonitrile | 上海大学 | 2023-08-22 | — | — | CN | disclosed |
| EP-1456197-B1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | GRUENENTHAL GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-7183274-B2 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-1456197-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053956-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | DPYD, CYP2D6, DHPS | TDP1 2104/4885ERN1 3571/4885PTPN1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.